News About Obesity Drug Acomplia (rimonabant) and Diabetes Available From www.AcompliaReport.com
First results from a one-year trial of Acomplia (rimonabant) in reducing risk factors for obese diabetics can be found in The Acomplia Report (http://www.AcompliaReport.com).
(PRWEB) June 11, 2005 -- First results from a one-year trial of Acomplia (rimonabant) in reducing risk factors for obese diabetics can be found in The Acomplia Report (http://www.AcompliaReport.com).
Acomplia Report (http://www.AcompliaReport.com) editors will provide the latest news about the obesity drug Acomplia (rimonabant) when it is presented at the American Diabetes Association meeting in San Diego.
The year-long Rimonabant in Obesity-Diabetes study, a multi-center trial which enrolled 1,000 obese patients with type 2 diabetes, will be the last of the four major Acomplia studies to report trial results before U.S. and European regulators are expected to act on Sanofi-Aventis' application to bring the drug to market.
In this trial, researchers compared weight-loss, improvements in metabolic variables, and reduction in cardiovascular risk factors for obese diabetics who took Acomplia compared to those on a placebo.
Announcement of the results of the RIO-Diabetes trial is slated for a symposium on "Late-Breaking Clinical Trials" set for 2 p.m. PDT June 12th.
Researchers have hinted privately to reporters that the results are consistent with the highly encouraging results from their three studies reported earlier -- RIO-North America, RIO-Europe and RIO-Lipids.
The fact that the results are being presented at the highest-profile symposium at the American Diabetes Association meeting -- only weeks after Sanofi filed for approval of the drug with the U.S. Food and Drug Administration and European regulators -- also strongly suggests more positive news is forthcoming.
News from the presentation will be posted late Sunday on the Acomplia Report (http://www.AcompliaReport.com).
Full coverage of expected news conferences related to the Acomplia (rimonabant) trials will also be posted on the Rimonabant Report (http://www.RimonabantReport.com).
The Acomplia Report (http://www.AcompliaReport.com) and the Rimonabant Report (http://www.RimonabantReport.com) are both published by Medical Week News, Inc., (http://www.MedicalWeek.org), which also publishes Obesity Week (http://www.ObesityWeek.org).
Milton Benjamin
772-559-4187
milt@medicalweek.org
###
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
